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Abstract
Drug-drug interactions (DDI) can cause severe adverse drug reactions and pose a major challenge to medication
therapy. Recently, informatics-based approaches are emerging for DDI studies. In this paper, we aim to identify
key pharmacological components in DDI based on large-scale data from DrugBank, a comprehensive DDI database.
With pharmacological components as features, logistic regression is used to perform DDI classification with a focus
on searching for most predictive features, a process of identifying key pharmacological components. Using univariate
feature selection with chi-squared statistic as the ranking criteria, our study reveals that top 10% features can achieve
comparable classification performance compared to that using all features. The top 10% features are identified to be
key pharmacological components. Furthermore, their importance is quantified by feature coefficients in the classifier,
which measures the DDI potential and provides a novel perspective to evaluate pharmacological components.
1. Introduction
Drug-Drug Interactions (DDI) can account for 30% of Adverse Drug Reactions (ADRs)1, which lead to 1.3 million
emergency department visits and 350,000 hospitalizations in the United States each year2. Recently, there is an
increasing trend of polypharmacy3, especially among the elderly people. According to the Centers for Disease Control
and Prevention, the percentage of the US population taking five or more prescription drugs in past 30 days increased
from 4.0% during 1988-1994 to 10.9% during 2011-2014. For seniors 65 years or older, the proportion increased from
13.8% to 40.7%4, which boosts the incidence of DDIs. Thus, identification of possible DDI before a drug is launched
into market becomes critical.
DDI can be broadly classified into two categories: pharmacokinetic (PK) and pharmacodynamic (PD) DDI. PK
DDIs are the cases when a drug affects the PK processes, namely, absorption, distribution, metabolism and excre-
tion (ADME) of another co-administered drug. This will lead to concentration variations of the parent drug or active
metabolite at the site of action. PD DDI would happen if one drug has an antagonistic, additive, synergistic or even
indirect effect on the action of another drug. Key pharmacological components involved in PK and PD DDI include
four groups: carrier, transporter, enzyme and target5. A carrier is a secreted protein which can bind drugs and carry
them to move around the biological fluids. A transporter is a membrane protein which can facilitate in the influx or
efflux of xenobiotics. An enzyme is engaged in the bio-transformation of many substances. A target is a biological
component which drugs can interact with to exert a direct pharmacodynamic effect. Carriers, transporters and enzymes
are usually involved in PK DDI while targets mainly mediate PD DDI.
Traditional strategies to identify DDI are often based on a series of in vitro and in vivo studies. When the in vitro experi-
ment results indicate that the compound interacts with certain pharmacological components, i.e., carriers, transporters,
enzymes and targets, subsequent in vivo experiments would be conducted to verify the interaction6. To accelerate
wet-lab DDI identification efficiency, in silico approaches can also be used, such as 1) predicting whether a compound
interacts with certain carrier, target, enzyme or transporter using in silico virtual screening approaches7 and 2) study-
ing mechanisms of a compound in ADME using various PKPD models8–12. However, most studies only test a limited
number of drugs at a time involving several selected pharmacological components, which are considered important
in DDI based on previous experience. However, one essential question remains unanswered: which pharmacological
components are most relevant to DDI and should be recruited in the follow-up studies, especially considering the high
cost of studies and long duration of experiments?
In the past decade, with the rise of ‘Big Data’, informatics-based DDI studies exploiting large-scale data are emerging.
These studies can be classified into two broad categories based on the goals: 1) DDI detection studies and 2) DDI
prediction studies. DDI detection studies focus on detecting novel DDI signals for existing drugs, such as mining
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into FDA Adverse Event Reporting System (FAERS), social media, literature, and electronic health records (EHR)
for potential DDI1,13–19. DDI prediction studies focus on predicting novel DDI signals for new drugs or new drug
combinations using drug knowledge databases5,20–32. Nonetheless, these studies are not aimed at understanding the
pharmacological components through which a DDI occurs, and the question above still remains unanswered.
In this study, we aim to identify important factors contributing to DDI, which is a feature selection problem per se
in the context of DDI classification. To achieve this goal, we conduct a DDI classification task with pharmacological
components as features, and select most contributing features as the most influential pharmacological components.
2. Methods
The experimental setup is illustrated in Figure 1. We embed the key pharmacological components identification in
a typical classification task and search for the most relevant features. We first generate different feature subsets by
keeping different proportions of all features in the training set using univariate feature selection method. We then
use these feature subsets on the testing set to perform DDI classification respectively. Finally, we evaluate classifica-
tion performances of these feature subsets for best feature subset selection. To make the identified pharmacological
components more reliable, this process is repeated 30 times.
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Figure 1: Methodology for Key Pharmacological Components Identification
2.1 DDI Classification
2.1.1 DDI Dataset Construction
DrugBank is a comprehensive drug database with basic drug information such as pharmacological components that a
drug interacts with, as well as a list of DDIs, which originate from drug package inserts and are usually treated as the
gold-standard, positive DDI33. In this study, we use the latest version 5.1.4 (released on 2019-07-02) of DrugBank as
the data source.
We first construct a drug information table with the following information: 1) drug types: ”small-molecule” or
”biotech”, 2) drug groups: ”experimental”, ”investigational” or ”approved”, and 3) pharmacological components inter-
acting with a drug: carriers, transporters, enzymes and targets. After parsing the DrugBank database in XML format,
we get 13,339 drug entries in total. We then construct a DDI table by extracting all the DDI records for each drug,
which results in 2,723,944 DDI records. In the final step of constructing DDI data repository, we narrow the study
scope to the 2,594 approved, small-molecule drugs, which form 3,363,121 unique drug-drug pairs. A drug-drug pair is
an instance in the DDI repository. Next, by querying the basic drug information table, we retrieve the pharmacological
components for each drug in all drug-drug pairs. By querying the DDI table, we label DDI status for each instance.
If the drug-drug pair is in the DDI table, then an interaction exists and the instance is labeled as a positive DDI case.
Otherwise, it is labeled as a negative DDI case. Among the 3,363,121 instances, there are 615,537 positive DDI cases
and the positive rate is 18.3%. The DDI data repository construction process is illustrated in Figure 2.
We randomly pick 200,000 DDI cases from the repository as the current DDI study dataset, with a positive rate of
18.3%.
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Figure 2: Construction of the DDI Data Repository
2.1.2 Feature Engineering
Since our study objective is to identify key pharmacological components, we use carrier(s), target(s), enzyme(s) and
transporter(s) interacting with the two drugs in each DDI instance as features. In the study dataset, a DDI instance I i
consists of two drugs Di, 1 and Di, 2. For drug Di, 1, the interacting carriers, transporters, enzymes and targets are de-
noted as carrieri, 1, transporteri, 1, enzymei, 1 and targeti, 1, respectively. Similarly, for drugDi, 2, its corresponding
pharmacological components are denoted as carrieri, 2, transporteri, 2, enzymei, 2 and targeti, 2, respectively.
One common hypothesis for the cause of a PK or PD DDI is that there are some overlaps in certain pharmacological
components which two drugs can both interact with5. Thus, we only retain the overlapping pharmacological compo-
nents for Di, 1 and Di, 2 in a given DDI instance I i to get carrieri, transporteri, enzymei and targeti. They are
then aggregated over all DDI instances to form Carrier, Transporter, Enzyme and Target and are converted into
binary vectors using one-hot encoding as features to classify DDI (Figure 3). In total, there are 498 features, including
16 carriers, 65 transporters, 62 enzymes and 355 targets.
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Figure 3: One-Hot Encoding for Pharmacological Components
2.1.3 Classifier
In this study, we adopt logistic regression (LR) as the classifier because of its high interpretability. LR uses a logistic
function to model a binary target variable Y with features X1, · · · , XD. The log odds of the event that Y = 1 is
defined in Eq. 1:
log e
P (Y = 1)
1− P (Y = 1) = β0 + β1X1 + · · ·+ βDXD (1)
where β1, · · · , βD are coefficients for features X1, · · · , XD. These coefficients can be interpreted in a straightforward
way. For example, if β1 = 1, then increasing X1 from 0 to 1 increases the odds of event Y = 1 by a factor e. In
our setting, for a given pharmacological component with β coefficient being 1, if two drugs can both interact with the
component, the interpretation is that the odds of a positive DDI is increased by e times.
To counteract the effect of imbalanced classes in our dataset, we adjust the weights to make them inversely proportional
to class frequencies. Other hyper parameters in the LR classifier are set based on 5-fold cross validation using the entire
study dataset, which consists of 200,000 DDI cases and 498 features. All the hyper parameters are kept constant during
subsequent experiments.
2.2 Feature Selection
The study datasets are randomly splitted into a training set (50%) and a testing set (50%). Univariate feature selection
is used to rank all features in the training set in a supervised way. Since the target variable and the features are all
binary vectors, we choose chi squared statistic as the ranking criteria. We thereby generate different feature subsets
by varying the top percentile of the ranked features, i.e., the proportion of features to be recruited in the classification
task. For example, with the whole feature set denoted as F , feature subset F P represents the top P% features in F
ranked by the chi squared statistic (P ∈ {5, 10, 15, · · · , 100}).
2.3 Feature Subset Selection
Each F P selected in the training set is applied in the DDI classification task. Classification performance is examined
by the following metrics, namely, accuracy, recall, precision, F1 socre, area under the Receiver Operating Curve
(AUROC) and area under the Precision Recall Curve (AUPRC). The classification performance reflects DDI predictive
ability of each F P. The best feature subset F P is expected to have the best classification performance. Note that the
DDI classification task is repeated 30 times by randomly splitting the study dataset 30 times to appeal to the central
limit theorem for later statistical analyses.
2.4 Identification of Key Features
With the top percentile P identified, we extract all the features in feature subset F P over 30 repeats. For each individual
feature, i.e., a pharmacological component, we also extract their corresponding β coefficients in the LR classifier as a
measure for DDI potential.
3. Results
3.1 Best Feature Subset
We test the classification performance of F P (P ∈ {5, 10, · · · , 100}) over 30 repeats and calculate the mean and 95%
confidence interval (CI) of the evaluation metrics (Figure 4). When the top 5% features are used, all the metrics have
the lowest value with statistical significance, which could be caused by insufficient number of features for classifi-
cation. When the top 10% features are used, accuracy, recall, precision and AUPRC reach the peak value. When P
increases from 10 to 100 with a step size 5, the metrics are either gradually decreasing or reached a plateau state.
Overall, F 10 can achieve comparable performance with F 100, i.e., the whole feature set F . Therefore, F 10 is the
optimal feature subset.
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Figure 4: DDI Classification Performance using Feature Subsets of Top P% Features (Mean ± 95% CI, N = 30)
3.2 Key Pharmacological Components in DDI
We extract individual features in all F 10 over 30 repeats. To further compare their importance, we extract their
corresponding β coefficients in the LR classifier as well as the number of occurrences over 30 repeats (Figure 5).
In total, there are 64 key pharmacological components identified as important in causing DDI, including 2 carriers
(12.5% of Carrier), 15 transporters (23.1% of Transporter), 15 enzymes (24.2% of Enzyme) and 32 targets (9% of
Target), which are discussed next.
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Figure 5: Identified Important Pharmacological Components for DDI Classification
Key Carriers
Serum albumin with a median β coefficient around 1 is a plasma protein which can non-specifically bind drugs. Studies
were conducted on its binding sites which can cause DDI34. Another carrier, alpha-1-acid glycoprotein 1, is also a
carrier involved in the binding and transporting of multiple drugs. When two drugs can both bind to this carrier, either
drug or both drugs can have altered distribution and a DDI is expected35.
Key Transporters
Important transporters in DDI revealed by our study are mainly in two categories: ATP-binding cassette (ABC) trans-
porters, such as ATP-binding cassette sub-family G member 2 (ABCG2, BCRP), bile salt export pump (BSEP) and
Multidrug Resistance Protein 1 (ABCB1, MDR1, P-gp), and solute carrier family (SLC) transporters, such as solute
carrier family 22 member 2 (SLC22A2, OCT2) and solute carrier organic anion transporter family 1B1 (SLCO1B1,
OATP1B1). A systematic review on membrane transporters in drug development has pointed out that these transporters
have a role in clinical DDI36. For instance, P-gp distributed in intestine, kidney proximal tubule, liver and blood brain
barrier can export a wide range of drugs, such as cyclosporine, doxorubicin, digoxin and loperamide. The role of P-gp
in absorption, distribution and excretion makes it to have a high potential to cause DDI. Another transporter, BSEP,
mainly located in hepatocytes and responsible for drug excretion, has median β coefficient around 4.5, which indicates
its prominent importance in DDI as well.
Key Enzymes
Phase I metabolizing enzymes such as Cytochromes P450 (CYPs) have long been perceived as a key factor in DDI37.
It is reported that in liver, a major organ for drug metabolism, the highest expressed CYP isoforms include CYP1A2,
CYP2C8, CYP2C9, CYP2E1 and CYP3A4, which are all manifested in the identification results38. Other isoform
such as CYP2B6, which demonstrates clinical significance in recent years, is also captured39. Several phase II me-
tabolizing enzymes such as UDP-glucuronosyltransferases (UGT), including UGT1-1, UGT1-9 and UGT2B7, have
median β coefficients higher than 2, indicating a non-negligible role that they play in DDI. Unlike CYP mediating
oxidation reactions, UGTs mainly catalyze conjugation reactions. For example, UGT2B7 converts codeine, an opioid
anagesic, into codeine 6-glucuronide, a major active metabolite responsible for 60% analgesic effect of codeine40.
Meanwhile, methadone, a medication to treat opioid use disorder, can inhibit UGT2B7 and substantially reduce the
plasma concentration of codeine 6-glucuronide to form a DDI with codeine41.
Key Targets
Identified targets mainly include the following categories: 1) 5-hydroxytryptamine (5-HT) receptors (a.k.a serotonin
receptors) and sodium-dependent serotonin transporters (a.k.a., serotonin transporter, SERT) which are the targets
for many antidepressant medications, 2) adrenergic receptors which correspond to adrenergic drugs, 3) dopamine
receptors whose targeted drugs are mainly used to treat Parkinson’s disease, 4) opioid receptors which are the targets
for opioid drugs, 5) GABA-A receptors whose agonists include benzodiazepines, 6) muscarinic acetylcholine receptors
(a.k.a cholinergic receptors) which correspond to antispasmodic drugs, and 7) prostaglandin G/H synthases (a.k.a.,
Cyclooxygenases, COX) which are the targets for non steroidal anti-inflammatory drugs (NSAIDs).
Among the 64 identified pharmacological components, 50% of them are targets. There are two reasons why drug
targets consists of the major group. First, there is a large number of features in the Target group. Secondly, PD DDI
mediated by drug targets exist more widely than PK DDI, because target agonists or antagonists directly strengthen
or weaken their therapeutic effect making PD DDI more likely to be detected. On the contrary, PK DDI mediated by
carriers, transporters and enzymes can lead to concentration variations, which, however, may not necessarily exert a
noticeable PD effect.
3.3 Insights for DDI Study
Two cases studies are conducted to generate insights for DDI studies.
Trending Pharmacological Components Group in DDI
We aggregate all the identified pharmacological components by the four groups, i.e., Carrier, Transporter, Enzyme and
Target (Figure 6), where the unpaired two-samples t-test is used to compare whether there is statistically significant
difference between different groups with regard to the β coefficients.
Target is the most influential group in DDI, with β coefficients significantly higher than the other three groups (p <
0.0001). On the contrary, Carrier is the least important group which has statistically lower coefficients than the other
three groups (p < 0.0001). For Enzyme and Transporter, Transporter has slightly higher coefficients than Enzyme
with statistical significance (p < 0.001), which demonstrates that drug transporters can contribute to DDI equally as
enzymes. Interestingly, it is not until in recent years that the significance of transporters has been well addressed by
researchers36. Our findings can be corroborated by the current DDI study trends.
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Figure 6: Comparison of Coefficients in Different Pharmacological Components Groups
Novel Measure beyond Amount and Activity
We extract all CYP isoforms and their corresponding coefficients over 30 repeats. Since all CYP isoforms occur in
each repeat resulting in sample size at 30, the unpaired two-samples t-test is used to examine the statistical significance
(Figure 7). CYP2A6, CYP2D6 and CYP1A2 with coefficients of no statistically significant differences are identified
to be the most important CYP isoforms in DDI, closely followed by CYP2C9 > CYP3A4 > CYP2C8 > CYP3A5 >
CYP2C19 > CYP2B6 > CYP2E1 > CYP1A1 > CYP3A7.
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Figure 7: Comparison of Different CYP Isoforms Coefficients (Mean ± 95% CI, N = 30)
In traditional DDI studies, the amount and activity of CYP isoforms measured via in vitro experiments provides prior
knowledge to predict the importance of different CYP isoforms in drug metabolism and DDI38. In our study, feature
importance can also act as a novel measure for DDI potential and allows evaluation of the CYP isoforms directly from
a DDI-centered perspective.
4. Discussion
Traditional routine DDI studies such as wet-lab experiments often require broad knowledge on pharmacological com-
ponents. Due to the high study cost and long experimental duration, it is infeasible to perform experiments on all
pharmacological components. Identification of most relevant carriers, transporters, enzymes and targets is critical in
wet-lab studies.
Different from other informatics-based DDI studies, our study focus on utilizing large-scale information on DDI
to generate insights and boost wet-lab study efficiency. In order to answer the question “which pharmacological
components are most relevant to DDI”, we conduct an informatics-based DDI study to demystify the underlying
key carriers, enzymes, targets and transporters in DDI. A machine-learning methodology based on classification and
feature selection is developed to identify key pharmacological components and strong literature evidence supports
our findings. Furthermore, by exploiting logistic regression, a classifier with interpretable feature coefficients, the
importance of the key components is also quantified, which can act as a novel and direct DDI-oriented measure to
evaluate the pharmacological components.
Our approach is not without its limitations. First, the nature of interaction between the drug and the pharmacolog-
ical component is not considered. At this stage, we only take into account whether a drug interacts with a specific
pharmacological component. In the current feature engineering process, we do not capture how a drug induces or
inhibits the pharmacological component, or if the drug is merely a substrate. The relationship between a drug and
its corresponding pharmacological component will be further explored. Secondly, DrugBank may not have the most
complete DDI information, and we will explore other potential data sources. In the future, in addition to the logistic
regression classifier, we will also explore deep learning classifiers, in particular those with interpretable capability.
5. Conclusion
In this paper, we use an informatics-based approach to study which pharmacological components are most relevant
to DDI. We identify a list of key pharmacological components including 2 carriers, 15 transporters, 15 enzymes and
32 targets. The quantified importance of these components in DDI in our study is consistent with current DDI study
trends and acts as a novel measure for pharmacological components from a DDI-oriented perspective.
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